

Research

Open Access

## Recombinant norovirus-specific scFv inhibit virus-like particle binding to cellular ligands

Khalil Ettayebi and Michele E Hardy\*

Address: Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717, USA

Email: Khalil Ettayebi - [kettayeb@montana.edu](mailto:kettayeb@montana.edu); Michele E Hardy\* - [mhardy@montana.edu](mailto:mhardy@montana.edu)

\* Corresponding author

Published: 31 January 2008

Received: 30 November 2007

*Virology Journal* 2008, 5:21 doi:10.1186/1743-422X-5-21

Accepted: 31 January 2008

This article is available from: <http://www.virologyj.com/content/5/1/21>

© 2008 Ettayebi and Hardy; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Noroviruses cause epidemic outbreaks of gastrointestinal illness in all age-groups. The rapid onset and ease of person-to-person transmission suggest that inhibitors of the initial steps of virus binding to susceptible cells have value in limiting spread and outbreak persistence. We previously generated a monoclonal antibody (mAb) 54.6 that blocks binding of recombinant norovirus-like particles (VLP) to Caco-2 intestinal cells and inhibits VLP-mediated hemagglutination. In this study, we engineered the antigen binding domains of mAb 54.6 into a single chain variable fragment (scFv) and tested whether these scFv could function as cell binding inhibitors, similar to the parent mAb.

**Results:** The scFv<sub>54.6</sub> construct was engineered to encode the light (V<sub>L</sub>) and heavy (V<sub>H</sub>) variable domains of mAb 54.6 separated by a flexible peptide linker, and this recombinant protein was expressed in *Pichia pastoris*. Purified scFv<sub>54.6</sub> recognized native VLPs by immunoblot, inhibited VLP-mediated hemagglutination, and blocked VLP binding to H carbohydrate antigen expressed on the surface of a CHO cell line stably transfected to express  $\alpha$  1,2-fucosyltransferase.

**Conclusion:** scFv<sub>54.6</sub> retained the functional properties of the parent mAb with respect to inhibiting norovirus particle interactions with cells. With further engineering into a form deliverable to the gut mucosa, norovirus neutralizing antibodies represent a prophylactic strategy that would be valuable in outbreak settings.

### Background

Noroviruses are non-enveloped positive strand RNA viruses that cause foodborne illness worldwide [1]. They are classified as NIAID Category B priority pathogens because they are easily transmitted person-to-person and can cause persistent epidemics. Outbreaks generally occur in semi-closed community settings including day care centers, retirement facilities and nursing homes, hospitals, schools, and military training and operations facilities. Large outbreaks on commercial cruise-liners have been well publicized, and such outbreaks illustrate the

rapid onset epidemic potential of noroviruses and a need for intervention measures that do not depend on pre-existing immunity. Recent data suggest the number of outbreaks attributable to noroviruses may be increasing [2].

The norovirus genome is a 7.7 kilobase RNA comprised of three open reading frames (ORF) [reviewed in [3]]. ORF1 codes for the nonstructural proteins that are processed co- and post-translationally by a single viral protease. ORF2 and ORF3 encode structural proteins VP1 and VP2, respectively, and form the icosahedral capsid. Ninety dim-

ers of VP1 assemble into virus-like particles (VLPs) when expressed in insect cells infected with a recombinant baculovirus [4]. VP1 folds into two major domains termed the shell (S) and protruding (P) domains [5,6]. The S domain consists of the N-terminal 280 amino acids and forms the icosahedron. The P domain is divided into subdomains P1 and P2 that participate in dimeric contacts that increase the stability of the capsid. The P2 domain is an insertion in the P1 domain and contains a hypervariable region implicated in receptor binding and immune reactivity, as well as in interactions with histoblood group antigens associated with susceptibility to norovirus infections [7-11].

Therapeutic antibodies have been used successfully in treatment regimens for diseases including cancer and rheumatoid arthritis, for transplant rejection, and against respiratory syncytial virus infections in children [reviewed in [12]]. Technological advances that include humanization to avoid undesirable immunogenicity, and improvements in stability and pharmacokinetics are strategies employed to improve the clinical utility of antibodies. Foremost among such strategies is the reduction of antigen binding domains to minimal fragments that retain reactivity with the targeted antigens [13]. Single chain variable fragments (scFv) are ~27 kDa recombinant proteins that consist of the light ( $V_L$ ) and heavy ( $V_H$ ) chain variable regions of a monoclonal antibody (mAb) expressed in a single construct where they are separated by a flexible peptide linker [14]. Intramolecular folding of the recombinant protein results in reconstitution of the antigen binding domain. These small proteins are relatively easily produced in high yield in recombinant bacterial or yeast expression systems [15-17]. Further manipulation and expression strategies have yielded forms of the scFv monomer where valency is increased by assembly of multimeric forms termed diabodies, triabodies and tetrabodies [13]. These multimers have been shown to be more stable and can be engineered to recognize more than one antigenic target [18,19].

We generated mAb to norovirus VLPs to characterize domains of VP1 that function in virus binding to cellular receptors [20]. One mAb (mAb 54.6) to the genogroup I reference strain Norwalk (NV) blocks binding of recombinant VLPs to CaCo-2 intestinal cells and inhibits VLP-mediated hemagglutination. In the current study, we engineered sequences encoding mAb 54.6 into an scFv to determine whether functional activity was retained in the isolated antigen binding domain. The data presented show the scFv from mAb 54.6 (scFv<sub>54.6</sub>) was expressed successfully in *Pichia pastoris* and retained the antigen binding and functional activity of the parent mAb. Engineered antibody fragments that block norovirus binding

to cells have potential as an on-site prophylactic strategy to prevent virus spread and contain epidemics.

## Results

### $V_L$ and $V_H$ domains of mAb 54.6 and design of scFv<sub>54.6</sub>

Anti-rNV mAb 54.6 recognizes non-denatured VP1, inhibits VLP-mediated hemagglutination, and blocks VLP binding to CaCo-2 cells. To determine whether functional activity of the mAb could be reduced to a smaller antigen binding domain, sequences encoding the  $V_L$  and  $V_H$  genes of mAb 54.6 were cloned from the hybridoma cells (Figure 1). A database search for homologies to known murine V genes was performed with the IgBLAST protocol. The  $V_L$  domain of mAb 54.6 is 98.9% identical to  $V_L$  genes in the V $\kappa$ -23-48 family [21], with the exception of a substitution of isoleucine for threonine at position 31 in the V $\kappa$ -CDR1. The  $V_H$  domain was amplified in a single form highly homologous to the  $V_H$ 7183 gene family [22] and is 96% identical to the  $V_H$ 50.1 gene.  $V_H$  genes derived from the  $V_H$ 7183 family are preferentially used by autoantibodies of various specificities [23]. However, some antibodies specific for foreign antigens such as galactan and the A/PR8/34 strain of influenza virus hemagglutinin also are encoded by  $V_H$  genes of this family [24,25].

The domain organization of the 245 amino acid scFv<sub>54.6</sub> consists of the  $V_L$  domain at the N terminus separated from the  $V_H$  domain at the C terminus by a peptide linker comprised of the sequence GGKGGGKGTGGKGGGKGS (Figure 1). The linker composition is a modification of the peptide linker previously described [26]. C-terminal myc and histidine tags are expressed in frame with scFv<sub>54.6</sub> to allow detection of recombinant protein by immunoblot and for downstream purification procedures.

### Production of scFv<sub>54.6</sub> in *P. pastoris* and reactivity with rNV VP1

The pPICZ $\alpha$ A vector contains the methanol-inducible AOX1 promoter for high level expression in *P. pastoris* and the  $\alpha$ -factor signal sequence from *Saccharomyces cerevisiae* for secretion of recombinant protein into the culture supernatant [27,28]. During secretion, the signal peptide is cleaved by the *P. pastoris* protease KEX2 (kexin), releasing soluble scFv<sub>54.6</sub> into the medium. Typical yields following induction of expression with methanol, purification and concentration, were approximately one mg of purified scFv<sub>54.6</sub> per liter of suspension culture. scFv<sub>54.6</sub> has a calculated molecular mass of approximately 29 kDa. Three closely migrating protein bands were detected by silver stain (Figure 2A). The top two bands strongly reacted with the anti c-myc mAb under both reducing and non-reducing conditions (Figure 2B). The exact composition of the two bands is not clear, but they likely are products of slightly different KEX protease cleavage sites at the N terminus of the protein, because the myc

```

                                                    VL-CDR1
1-  D I L L T Q S P A I L S V S P G E R V S F S C R A S Q S I G
                                                    VL-CDR2
31-  I S I H W Y Q Q R T N G S P R L L I K Y A S E S I S G I P S
61-  R F S G S G S G T D F T L S I N S V E S E D I A D Y Y C Q Q
                                                    Peptide linker
91-  S N S W P W T F G G G T K L E I K G G K G S G G K G T G G K
G S G G K G S E V K L V E S G G D L V Q P G G S L K L S C A
                                                    VH-CDR1
24-  T S G F T F S D Y Y M Y W V R Q T P E K R L E W V A Y I S S
                                                    VH-CDR2
54-  G G G S T F Y P D T V K G R F T I S R D N A K N T L Y L Q M
84-  S R L K S D D T A M Y Y C A R A Y H G N Y F D Y W G Q G T T
114- L T V S S
    
```

**Figure 1**


Amino acid sequence and domain organization of scFv<sub>54.6</sub>. V<sub>L</sub> (red) and V<sub>H</sub> (blue) chains are shown as a single sequence joined together with a 20 amino acid linker (shaded). Complementarity determining regions (CDRs) of V<sub>L</sub> and V<sub>H</sub> are underlined. Amino acid numbering is according to Kabat [43].

epitope tag recognized by the antibody resides at the C terminus. In support of this interpretation, N-terminal amino acid sequence analysis of three forms of recombinant protein rhIFN-λ1 showed proteolytic processing adjacent to and outside of the KEX2 cleavage site [29].


Recognition of rNV VP1 by mAb 54.6 is conformation dependent because this antibody reacts in immunoblots only when VP1 has not been denatured by boiling in SDS and β-mercaptoethanol [20]. scFv<sub>54.6</sub> was tested for the ability to bind rNV VP1 in immunoblots to determine whether the fragment retained reactivity of the parent mAb. Immunoblots were probed with scFv<sub>54.6</sub> and binding to rNV VP1 was detected with anti-c-myc mAb and goat anti-mouse secondary antibody. Similar to mAb 54.6, scFv<sub>54.6</sub> recognized VP1 only under non-denaturing, non-reducing conditions (Figure 3). Neither the mAb 54.6 nor scFv<sub>54.6</sub> recognized denatured VP1.

**scFv<sub>54.6</sub> blocks rNV VLP-mediated hemagglutination**

Norovirus VLPs agglutinate red blood cells in a type-specific manner [30] and mAb 54.6 inhibits this activity for rNV VLPs [20]. To determine whether scFv<sub>54.6</sub> inhibited hemagglutination, rNV VLPs were mixed with type O rbc in the presence or absence of scFv<sub>54.6</sub> or mAb 54.6. Figure 4A shows that scFv<sub>54.6</sub> successfully blocked rNV VLP-mediated hemagglutination in a dose-dependent manner. The lowest inhibitory concentration was 3.0 μg and 0.375 μg of scFv<sub>54.6</sub> and the parent mAb, respectively (Figures 4A




**Figure 2** Expression of scFv<sub>54.6</sub> in *P. pastoris*. (A) SDS-PAGE analysis of affinity chromatography purified scFv<sub>54.6</sub> after 72 hrs induction. (B) Purified scFv<sub>54.6</sub> electrophoresed under non-reducing (NR) and reducing (R) conditions was probed with anti-c-myc mAb and HRP-conjugated goat anti-mouse IgG.



**Figure 3**  
Western blot analysis of rNV VPI probed with (A) mAb 54.6 and (B) scFv<sub>54.6</sub> under non-denaturing (left panel) and denaturing (right panel) conditions.

and 4B), yielding an HI titer for scFv<sub>54.6</sub> eight-fold lower than that of mAb 54.6. While it is possible that part of the difference in HI titer can be attributed to slight differences in concentration, it is likely that the lower HI titer of



**Figure 4**  
Dose-dependent hemagglutination inhibition by recombinant scFv<sub>54.6</sub>. Numbers above the wells indicate the amount of antibody in the reactions in µg. (A) scFv<sub>54.6</sub> (B) mAb 54.6 (C) PBS-H and rbc only. (+) indicates presence of rNV particles, (-) indicates absence of rNV particles.

scFv<sub>54.6</sub> reflects the monovalent binding activity of the fragment.

**scFv<sub>54.6</sub> blocks binding of rNV VLPs to CHO-FTB<sub>KE</sub> cells**


CHO cells do not express ABH histoblood group antigens, but CHO cells stably transfected with the rat FTB gene encoding α 1,2-FT confers the ability to bind rNV VLPs to these cells [31]. scFv<sub>54.6</sub> was tested for the ability to block binding of rNV VLPs to CHO-FTB<sub>KE</sub> cells. In the absence of antibody, 48.2% of cells bound VLPs (Figure 5). When VLPs were pre-incubated with scFv<sub>54.6</sub>, the percentage of positive cells was reduced to 10.2%. No reduction in binding was observed with samples from non-expressing X33 culture subjected to the same purification procedure as the scFv<sub>54.6</sub> (see Figure 2A). These results suggest scFv<sub>54.6</sub> is able to block binding of rNV VLPs to H type antigen on the cell surface.

**Discussion**

Immunity to noroviruses is complex and the correlates of protection from re-infection are unclear. Short-term immunity can be induced by prior infection, but long-lasting immunity apparently is more difficult to achieve. Gastroenteritis caused by norovirus generally is a self-limiting disease. However, the ease in which noroviruses are transferred by person-to-person spread suggest inhibitors designed to interfere with the initial steps of virus infection could reduce the duration of illness, shedding of infectious virus, and the number of susceptible individuals in a population. This issue is particularly relevant in semi-closed communities including nursing homes and daycare centers, where age may affect the efficacy of vaccines. We envision that inhibitors will be easily administered on-site as necessary and will by design, be independent of an adaptive immune response.

*P. pastoris* was chosen for scFv<sub>54.6</sub> expression because of reported high protein yield, low levels of glycosylation, simplicity of the culture medium and protein solubility. Numerous scFvs have been produced in *P. pastoris* with variable yields ranging from 0.4 to 20 mg/L [26,32,33]. We have shown that scFv<sub>54.6</sub> expressed in *P. pastoris* at yields of ~1.0 mg/L retain the inhibitory functions of the parent mAb, suggesting humanized derivatives of these fragments could prove useful for development of anti-norovirus prophylactics.

Antibodies have received significant interest as biopharmaceuticals. At least 18 mAb are in use in humans and > 100 are in clinical trials as therapeutics for treatment of cancer and chronic inflammatory diseases, and for prevention of transplant organ rejection [12]. Likewise, engineered smaller domains consisting of the functional antigen binding domains are viable alternatives to the costs associated with humanization and production of



**Figure 5**

scFv<sub>54,6</sub> blocks the binding of rNV VLPs to CHO-FTB<sub>KE</sub> cells. rNV VLPs were incubated with CHO-FTB<sub>KE</sub> cells in the presence or absence of scFv<sub>54,6</sub> and sorted by flow cytometry (A) VLP binding detected by incubation with scFv<sub>54,6</sub> followed by anti-c-myc mAb and PE-conjugated goat anti-mouse antibody. (B) VLP binding detected by incubation with anti rNV MAb 72.1 PE-conjugated goat anti-mouse and (C) scFv<sub>54,6</sub> were pre-incubated with VLPs for one hour prior to addition to the cells. Bound VLPs were detected by MAb 72.1.

mAb in mammalian cell culture systems [13]. Monovalent scFv are easily produced in high yield in recombinant bacterial or yeast expression systems, and when secreted into the medium, are readily purified to homogeneity by scalable purification procedures. scFv also can be designed to be bispecific, or engineered to preferentially form multimers including diabodies, triabodies, and tetrabodies that increase valency [13]. These multivalent properties with consequent increased avidity are particularly relevant for prophylaxis of viral diseases because, similar to other cellular receptor-ligand interactions, viral attachment proteins engage multiple copies of receptors on the cell surface.

Several examples of antibody fragments capable of neutralizing virus infection both in vitro and in vivo have been reported. For example, fragments selected from a human scFv library for reactivity with the West Nile virus envelope protein protected mice against lethal virus challenge when administered both prior to or shortly after infection [34]. Recombinant virus-specific scFv efficiently neutralized human papillomavirus infection in culture [35]. Affinity-selected scFv against hepatitis B virus also neutralized infection in vitro [36], and purified scFv that recognize intercellular adhesion molecule ICAM-1 effectively blocked transmission of HIV across an epithelial cell monolayer both in vitro and in a small animal model [37]. Together, these data illustrate the utility of scFv as a viable way to provide passive immunity to viral infections.

Our studies were approached with the idea that engineered antibody fragments could provide a rapidly deliverable substance for protection against norovirus infection where the potential for epidemics is heightened in semi-closed community settings. However, successful delivery of soluble proteins, including scFv, to the gut is unlikely because of potential instability from exposure to gut proteases. Recently, pathogen-specific scFv expressed on the surface of probiotic lactobacilli provided protection in small animal models of enteric viral infection [38]. This or a similar system that is amenable to oral administration could provide scaffolding for stable presentation of norovirus neutralizing scFv to the gut.

The antigenic specificity in the norovirus capsid lies primarily in the hypervariable P2 domain of VP1, and ideally, antibody fragments would be reactive with multiple strains. Genogroup II.4 strains currently are the predominant strains circulating worldwide, but others also have been reported [2,39-42]. In the absence of broadly cross-reactive antibodies, the ability to manipulate scFv fragments into bispecific molecules suggests these neutralizing fragments can be engineered to cover a combination

of antigenic types within a single delivery system. Construction of such bispecific fragments is underway.

## Material and methods

### Cloning of variable domain genes

Total RNA was isolated from hybridoma 54.6 [20] with the RNeasy Mini kit (Qiagen). Reverse transcription (RT) was conducted with 5 µg of total RNA using M-MLV RT (Invitrogen) and 3' oligonucleotides MVK-R and MVH-R (Table 1) for first-strand synthesis of cDNA corresponding to the variable regions of the light and heavy chains, V<sub>L</sub> and V<sub>H</sub>, respectively. Two µl of the cDNA reaction were used in PCR reactions conducted with degenerate 5' oligonucleotides for leader sequences (Table 1) and the 3' oligonucleotides used in the RT reaction. A single PCR amplicon obtained in each reaction was cloned into the pCR2.1 TOPO vector (Invitrogen), and sequenced using M13 reverse and M13 forward (-20) primers. The V<sub>L</sub> and V<sub>H</sub> sequences then were amplified from the pTOPO clones using the oligonucleotides described in Table 2. Both V<sub>L</sub> and V<sub>H</sub> PCR products were digested with *Kpn* I and ligated with T4 DNA ligase. The ligation products were used as templates to amplify the joined V<sub>L</sub> and V<sub>H</sub> regions separated by a 60 bp linker. The resulting PCR products then were cloned into the *Pichia pastoris* expression vector pPICZαA (Invitrogen) utilizing the *Eco*R I and *Xba* I restriction sites to yield pPICZαA-scFv<sub>54.6</sub>. Colonies were selected on zeocin-containing low salt agar plates containing 1% tryptone, 0.5% yeast extract, 0.5% sodium chloride and 25 µg/ml zeocin.

### Transformation of *P. pastoris* X33 and selection of recombinants

*P. pastoris* strain X33 was transformed with 10 µg of *Pme* I-linearized pPICZαA-scFv<sub>54.6</sub> following the Easysselect *Pichia* expression protocol (Invitrogen). In brief, electrocompetent cells were prepared from 200 ml of YPD medium inoculated with a fresh culture of *P. pastoris* X33 and incubated at 29°C, shaking at 250 rpm until the OD<sub>600 nm</sub> reached 1.3. The cells then were harvested by

centrifugation for five minutes at 1,500 × g, washed twice with sterile ice-cold water and once with 10 ml of ice-cold 1 M sorbitol, and then suspended in 0.5 ml of 1 M sorbitol. Electroporation was conducted by mixing 80 µl of this cell suspension with 10 µg of linearized pPICZαA-scFv<sub>54.6</sub> in a 0.2-cm cuvette. The cells were pulsed with 1.5 kV at a resistance setting of 129 ohms using a BTX ECM 630 electroporator. One ml of 1.0 M sorbitol was immediately added to the pulsed cells which then were transferred to a 15 ml tube and incubated for two hours at 29°C. Cells were plated onto YPD agar supplemented with 1.0 M sorbitol and containing 100 µg/ml of zeocin. Colonies were screened for multi-copy recombinants by patching onto YPD agar plates containing concentrations of zeocin ranging from 100 to 2,000 µg/ml. Recombinants selected on 2,000 µg/ml zeocin were screened for Met<sup>+</sup> phenotype by streaking onto minimal methanol agar medium and inserts were confirmed by PCR.

### scFv expression and purification

scFv<sub>54.6</sub> expression was conducted by growing recombinants in 50 ml buffered complex glycerol medium (BGM, pH 6.0) for 18 hrs at 29°C. Cells cultured to log phase were harvested by centrifugation at 1,500 × g, diluted to an OD<sub>600 nm</sub> of 1.0 in buffered complex methanol medium (BMM, pH 6.0) to induce expression, and then incubated for 72 hrs at 25°C in a shaking incubator at 250 rpm. At each 24 hour time point, 100% methanol was added to a final concentration of 1.0%. Casamino acids were added to BMM to a final concentration of 1.0% to reduce proteolysis. One ml samples were taken at selected time points and supernatants were analyzed for scFv<sub>54.6</sub> expression by SDS-PAGE and immunoblotting using anti-c-myc (Clontech) as the primary antibody.

The pre-cleared supernatant from induced cultures was precipitated by addition of ammonium sulfate to 45% saturation and incubated overnight at 4°C. Proteins were harvested by centrifugation for 25 minutes at 6,700 × g and then dialyzed against sodium phosphate saline buffer

**Table 1: Degenerate oligonucleotides for PCR amplification of V<sub>L</sub> and V<sub>H</sub> of mAb 54.6**

MVH-R	5'- GAC HGA TGG GGS TGT YGT GCT AGC TGN RGA GAC DGT GA -3'
MVK-R	5'- GGA TAC AGT TGG TGC AGT CGA CTT ACG TTT KAT TTC CAR CTT -3'
VK1-F	5'- GGG GAT ATC CAC CAT GGA GAC AGA CAC ACT CCT GCT AT -3'
VK2-F	5'- GGG GAT ATC CAC CAT GGA TTT TCA AGT GCA GAT TTT CAG -3'
VK3-F	5'- GGG GAT ATC CAC CAT GGA GWC ACA KWC TCA GGT CTT TRT A -3'
VK4-F	5'- GGG GAT ATC CAC CAT GKC CCC WRC TCA GYT YCT KGT -3'
VK5-F	5'- GGG GAT ATC CAC CAT GAA GTT GCC TGT TAG GCT GTT G -3'
VH1-F	5'- GGG GAT ATC CAC CAT GGR ATG SAG CTG KGT MAT SCT CTT -3'
VH2-F	5'- GGG GAT ATC CAC CAT GRA CTT CGG GYT GAG CTK GGT TTT -3'
VH3-F	5'- GGG GAT ATC CAC CAT GGC TGT CTT GGG GCT GCT CTT CT -3'
VH4-F	5'- GGG GAT ATC CAC CAT GAT RGT GTT RAG TCT TYT GTR CCT G -3'

**Table 2: Primers for cloning V<sub>L</sub> and V<sub>H</sub> of mAb 54.6 into *P. pastoris* expression vector pPICZαA**

VKF-54.6	5'- CAC GAA TTC GAC ATC TTG CTG ACT CAG TCT CCA GCC -3'
VKLR-54.6	5'- CTA CGG TAC CCT TAC CTC CAG ATC CCT TAC CTC CTT TGA TTT CCA ACT TGG TGC C -3'
VHLF-54.6	5'- CAC GGG TAC CGG AGG TAA GGG ATC TGG AGG TAA GGG ATC TGA AGT GAA ATT GGT GGA GTC -3'
VHR-54.6	5'- GGC ACT CTA GAG AGG AGA CAG TGA GAG TGG TGC C -3'

(50 mM monobasic sodium phosphate, 150 mM NaCl, pH 7.4). The dialysate was diluted with an equal volume of Ni-NTA buffer (50 mM monobasic sodium phosphate, 300 mM NaCl, pH 8.0) containing 25 mM imidazole and then incubated with Ni-NTA beads for 20 minutes at 4°C with end-over-end rotation. Beads were collected by centrifugation for two minutes at 800 × g and then washed five times with wash buffer (50 mM monobasic sodium phosphate, 300 mM NaCl, 20 mM imidazole, pH 8.0). His-tagged proteins were eluted with Ni-NTA buffer containing 250 mM imidazole, dialyzed against sodium phosphate buffer, pH 6.5, and concentrated by ultrafiltration through a Centricon Plus-20 column (Millipore).

#### Hemagglutination inhibition assay (HI)

The HI assay was performed as described previously [20]. In brief, 50 µl serial dilutions of purified scFv<sub>54.6</sub> or mAb 54.6 in sterile PBS-H (0.01 M sodium phosphate, 0.15 M sodium chloride, pH 5.5) were added to the wells of a vinyl flexible V-bottom 96-well plate (Costar), followed by addition of 50 µl of a 0.5 % suspension of type O red blood cells. Ten µl of VLPs (5 ng/ml in PBS-H) or PBS-H were added to the appropriate wells indicated in the figure legend. The plate was gently agitated and incubated for two hours at 4°C.

#### Construction of CHO-FTB<sub>KE</sub> cells and VLP blocking assays

A stable Chinese Hamster Ovary (CHO) cell line that expresses α 1,2-fucosyltransferase (α 1,2-FT) was constructed as previously described [31]. The rat FTB gene encoding α 1,2-FT was amplified by RT-PCR from total RNA isolated from rat colon using oligonucleotides FTB-F (5' CAAGGATCCATGGCCAGCGCCAGGTT-3') and FTB-R (5' CACCTCGAGTTAGTGCITTAAGGAGTGGGGAC-3'). The PCR amplicon was cloned in *Bam*HI and *Xho*I sites of pCDNA3.1/Myc-His(+)-A vector (Clontech). CHO-K1 cells were transfected with the FTB cDNA and stably maintained in RPMI containing 0.4 mg/ml G418. Expression of α 1,2-FT was confirmed by binding of FITC-conjugated UEA-lectin as previously described [31].

The ability of scFv<sub>54.6</sub> to block binding of VLPs to cells was measured by flow cytometry using R-Phycoerythrin (PE)-conjugated anti-mouse IgG (Jackson Immunoresearch Laboratories). Binding assays were performed as described previously [31]. Briefly, 990 ng of VLPs diluted

in PBS (pH 6.7) containing 0.1% gelatin were incubated for two hours at 4°C in the presence or in the absence of scFv<sub>54.6</sub> (5 µg/ml) or control IgG Fab fragment (Jackson Immunoresearch Labs). The reactions were mixed with 2 × 10<sup>5</sup> CHO-FTB<sub>KE</sub> cells and incubated for another two hours. Cells were washed and VLP binding was detected by incubation for one hour with anti-rNV mAb 72.1 [20] followed by a 45 minute incubation with PE-conjugated goat anti-mouse antibody at a final concentration of 2.0 µg/ml. MAb 72.1 recognizes rNV particles but is different from mAb 54.6, as their V<sub>L</sub> and V<sub>H</sub> sequences are not identical (unpublished data). Fluorescent cells were counted on a FACSCalibur (Becton Dickinson) and the data were analyzed with CellQuest Pro software (version 5.2.1; BD Biosciences).

#### Competing interests

The author(s) declare that they have no competing interests.

#### Authors' contributions

KE performed all of the experimental work in this study and assisted in preparation of the manuscript. MEH conceived of the study, participated in study design, jointly prepared the manuscript and is responsible for oversight of the entire project. Publication of the final manuscript is approved by the authors.

#### Acknowledgements

This work was sponsored in part by a subcontract to MEH from LigoCyte Pharmaceuticals, Bozeman, MT, through US Army Medical Research and Materiel Command Contract Number DAM17-01-C-0040. The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy or decision, unless so designated by other documentation. Additional support was provided by the Montana Ag Experiment Station and PHS grant P20 RR020185.

#### References

- Green KY: **Human caliciviruses**. In *Fields Virology* Edited by: Knipe DM and Howley PM. Philadelphia, PA, Lippincott Williams & Wilkins; 2001:841-874.
- Widdowson MA, Monroe SS, Glass RI: **Are noroviruses emerging?** *Emerg Infect Dis* 2005, **11**:735-737.
- Hardy ME: **Norovirus protein structure and function**. *FEMS Microbiol Lett* 2005, **253**:1-8.
- Jiang X, Wang M, Graham DY, Estes MK: **Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein**. *J Virol* 1992, **66**:6527-6532.
- Prasad BV, Rothnagel R, Jiang X, Estes MK: **Three-dimensional structure of baculovirus-expressed Norwalk virus capsids**. *J Virol* 1994, **68**:5117-5125.

6. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK: **X-ray crystallographic structure of the Norwalk virus capsid.** *Science* 1999, **286**:287-290.
7. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS: **Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice.** *J Virol* 2002, **76**:12335-12343.
8. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendou J, Baric R: **Human susceptibility and resistance to Norwalk virus infection.** *Nat Med* 2003, **9**:548-553.
9. Hutson AM, Atmar RL, Graham DY, Estes MK: **Norwalk virus infection and disease is associated with ABO histo-blood group type.** *J Infect Dis* 2002, **185**:1335-1337.
10. Hutson AM, Atmar RL, Marcus DM, Estes MK: **Norwalk virus-like particle hemagglutination by binding to h histo- blood group antigens.** *J Virol* 2003, **77**:405-415.
11. Hutson AM, Atmar RL, Estes MK: **Norovirus disease: changing epidemiology and host susceptibility factors.** *Trends Microbiol* 2004, **12**:279-287.
12. Brekke OH, Sandlie I: **Therapeutic antibodies for human diseases at the dawn of the twenty-first century.** *Nat Rev Drug Discov* 2003, **2**:52-62.
13. Holliger P, Hudson PJ: **Engineered antibody fragments and the rise of single domains.** *Nat Biotechnol* 2005, **23**:1126-1136.
14. Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, Warren F, Keck P, Oppermann H: **Medical applications of single-chain antibodies.** *Int Rev Immunol* 1993, **10**:195-217.
15. Miller KD, Weaver-Feldhaus J, Gray SA, Siegel RW, Feldhaus MJ: **Production, purification, and characterization of human scFv antibodies expressed in *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Escherichia coli*.** *Protein Expr Purif* 2005, **42**:255-267.
16. Lamberski JA, Thompson NE, Burgess RR: **Expression and purification of a single-chain variable fragment antibody derived from a polyol-responsive monoclonal antibody.** *Protein Expr Purif* 2006, **47**:82-92.
17. D'Alatri L, Di Massimo AM, Anastasi AM, Pacilli A, Novelli S, Saccinto MP, De Santis R, Mele A, Parente D: **Production and characterization of a recombinant single-chain anti ErbB2-clavin immunotoxin.** *Anticancer Res* 1998, **18**:3369-3373.
18. Holliger P, Winter G: **Engineering bispecific antibodies.** *Curr Opin Biotechnol* 1993, **4**:446-449.
19. Holliger P, Prospero T, Winter G: **"Diabodies": small bivalent and bispecific antibody fragments.** *Proc Natl Acad Sci U S A* 1993, **90**:6444-6448.
20. Lochridge VP, Jutila KL, Graff JW, Hardy ME: **Epitopes in the P2 domain of norovirus VP1 recognized by monoclonal antibodies that block cell interactions.** *J Gen Virol* 2005, **86**:2799-2806.
21. Pech M, Hocht J, Schnell H, Zachau HG: **Differences between germ-line and rearranged immunoglobulin V kappa coding sequences suggest a localized mutation mechanism.** *Nature* 1981, **291**:668-670.
22. Williams GS, Martinez A, Montalbano A, Tang A, Mauhar A, Ogwaro KM, Merz D, Chevillard C, Riblet R, Feeney AJ: **Unequal VH gene rearrangement frequency within the large VH7183 gene family is not due to recombination signal sequence variation, and mapping of the genes shows a bias of rearrangement based on chromosomal location.** *J Immunol* 2001, **167**:257-263.
23. Bellon B, Manheimer-Lory A, Monestier M, Moran T, Dimitriu-Bona A, Alt F, Bona C: **High frequency of autoantibodies bearing cross-reactive idiotopes among hybridomas using VH7183 genes prepared from normal and autoimmune murine strains.** *J Clin Invest* 1987, **79**:1044-1053.
24. Clarke SH, Huppi K, Ruezinsky D, Staudt L, Gerhard W, Weigert M: **Inter- and intracloal diversity in the antibody response to influenza hemagglutinin.** *J Exp Med* 1985, **161**:687-704.
25. Hartman AB, Rudikoff S: **VH genes encoding the immune response to beta-(1,6)-galactan: somatic mutation in IgM molecules.** *EMBO J* 1984, **3**:3023-3030.
26. Cunha AE, Clemente JJ, Gomes R, Pinto F, Thomaz M, Miranda S, Pinto R, Moosmayer D, Donner P, Carrondo MJ: **Methanol induction optimization for scFv antibody fragment production in *Pichia pastoris*.** *Biotechnol Bioeng* 2004, **86**:458-467.
27. Tschopp JF, Brust PF, Cregg JM, Stillman CA, Gingeras TR: **Expression of the lacZ gene from two methanol-regulated promoters in *Pichia pastoris*.** *Nucleic Acids Res* 1987, **15**:3859-3876.
28. Scorer CA, Buckholz RG, Clare JJ, Romanos MA: **The intracellular production and secretion of HIV-1 envelope protein in the methylotrophic yeast *Pichia pastoris*.** *Gene* 1993, **136**:111-119.
29. Xie YF, Chen H, Huang BR: **Expression, purification and characterization of human IFN-lambda1 in *Pichia pastoris*.** *J Biotechnol* 2007, **129**:472-480.
30. Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow AL, Jiang X: **Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns.** *J Virol* 2005, **79**:6714-6722.
31. Marionneau S, Ruvoen N, Mouillac-Vaidye B, Clement M, Cailleau-Thomas A, Ruiz-Palacois G, Huang P, Jiang X, Le Pendu J: **Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals.** *Gastroenterology* 2002, **122**:1967-1977.
32. Emberson LM, Trivett AJ, Blower PJ, Nicholls PJ: **Expression of an anti-CD33 single-chain antibody by *Pichia pastoris*.** *J Immunol Methods* 2005, **305**:135-151.
33. Hu S, Li L, Qiao J, Guo Y, Cheng L, Liu J: **Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in *Pichia pastoris*.** *Protein Expr Purif* 2006, **47**:249-257.
34. Gould LH, Sui J, Foellmer H, Oliphant T, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, de Silva AM, Diamond MS, Koski RA, Marasco WA, Fikrig E: **Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.** *J Virol* 2005, **79**:14606-14613.
35. Culp TD, Spatz CM, Reed CA, Christensen ND: **Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.** *Virology* 2007, **361**:435-446.
36. Park SG, Jung YJ, Lee YY, Yang CM, Kim IJ, Chung JH, Kim IS, Lee YJ, Park SJ, Lee JN, Seo SK, Park YH, Choi IH: **Improvement of neutralizing activity of human scFv antibodies against hepatitis B virus binding using CDR3 V(H) mutant library.** *Viral Immunol* 2006, **19**:115-123.
37. Chancey CJ, Khanna KV, Seegers JF, Zhang GW, Hildreth J, Langan A, Markham RB: **Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer.** *J Immunol* 2006, **176**:5627-5636.
38. Pant N, Hultberg A, Zhao Y, Svensson L, Pan-Hammarstrom Q, Johansen K, Pouwels PH, Ruggeri FM, Hermans P, Frenken L, Boren T, Marcotte H, Hammarstrom L: **Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea.** *J Infect Dis* 2006, **194**:1580-1588.
39. Fankhauser RL, Monroe SS, Noel JS, Humphrey CD, Bresee JS, Parashar UD, Ando T, Glass RI: **Epidemiologic and molecular trends of "Norwalk-like viruses" associated with outbreaks of gastroenteritis in the United States.** *J Infect Dis* 2002, **186**:1-7.
40. Blanton LH, Adams SM, Beard RS, Wei G, Bulens SN, Widdowson MA, Glass RI, Monroe SS: **Molecular and epidemiologic trends of caliciviruses associated with outbreaks of acute gastroenteritis in the United States, 2000-2004.** *J Infect Dis* 2006, **193**:413-421.
41. Vinje J, Koopmans MP: **Molecular detection and epidemiology of small round-structured viruses in outbreaks of gastroenteritis in the Netherlands.** *J Infect Dis* 1996, **174**:610-615.
42. Siebenga JJ, Vennema H, Duizer E, Koopmans MP: **Gastroenteritis caused by norovirus GGII.4, The Netherlands, 1994-2005.** *Emerg Infect Dis* 2007, **13**:144-146.
43. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C: **Sequences of proteins of immunological interest.** *Volume NIH Publication NO. 91-3242.* National Technical Information Services (NTIS); 1991.